vs
Helmerich & Payne, Inc.（HP）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Helmerich & Payne, Inc.的季度营收约是Revvity的1.3倍（$981.1M vs $772.1M），Revvity净利率更高（12.7% vs -9.9%，领先22.6%），Helmerich & Payne, Inc.同比增速更快（45.4% vs 5.9%），Revvity自由现金流更多（$161.8M vs $114.9M），过去两年Helmerich & Payne, Inc.的营收复合增速更高（19.7% vs 9.0%）
Helmerich & Payne（简称H&P）是总部位于美国俄克拉荷马州塔尔萨的跨国石油钻探承包商，为油气勘探开发企业提供钻井及相关配套服务。公司1998年推出的FlexRigs系列钻井平台广泛应用于非常规页岩地层钻探作业，是全球最大的陆上钻探服务商之一。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
HP vs RVTY — 直观对比
营收规模更大
HP
是对方的1.3倍
$772.1M
营收增速更快
HP
高出39.6%
5.9%
净利率更高
RVTY
高出22.6%
-9.9%
自由现金流更多
RVTY
多$46.9M
$114.9M
两年增速更快
HP
近两年复合增速
9.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $981.1M | $772.1M |
| 净利润 | $-96.7M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | -6.1% | 14.5% |
| 净利率 | -9.9% | 12.7% |
| 营收同比 | 45.4% | 5.9% |
| 净利润同比 | -276.6% | 3.9% |
| 每股收益（稀释后） | $-0.98 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HPRVTY
| Q4 25 | $981.1M | $772.1M | ||
| Q3 25 | $953.8M | $698.9M | ||
| Q2 25 | $1.0B | $720.3M | ||
| Q1 25 | $1.0B | $664.8M | ||
| Q4 24 | $674.6M | $729.4M | ||
| Q3 24 | $691.3M | $684.0M | ||
| Q2 24 | $695.1M | $691.7M | ||
| Q1 24 | $685.1M | $649.9M |
净利润HPRVTY
| Q4 25 | $-96.7M | $98.4M | ||
| Q3 25 | $-57.4M | $46.7M | ||
| Q2 25 | $-162.8M | $53.9M | ||
| Q1 25 | $1.7M | $42.2M | ||
| Q4 24 | $54.8M | $94.6M | ||
| Q3 24 | $75.5M | $94.4M | ||
| Q2 24 | $88.7M | $55.4M | ||
| Q1 24 | $84.8M | $26.0M |
毛利率HPRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率HPRVTY
| Q4 25 | -6.1% | 14.5% | ||
| Q3 25 | -0.1% | 11.7% | ||
| Q2 25 | -12.4% | 12.6% | ||
| Q1 25 | 4.2% | 10.9% | ||
| Q4 24 | 13.3% | 16.3% | ||
| Q3 24 | 15.4% | 14.3% | ||
| Q2 24 | 16.0% | 12.4% | ||
| Q1 24 | 16.1% | 6.8% |
净利率HPRVTY
| Q4 25 | -9.9% | 12.7% | ||
| Q3 25 | -6.0% | 6.7% | ||
| Q2 25 | -15.7% | 7.5% | ||
| Q1 25 | 0.2% | 6.4% | ||
| Q4 24 | 8.1% | 13.0% | ||
| Q3 24 | 10.9% | 13.8% | ||
| Q2 24 | 12.8% | 8.0% | ||
| Q1 24 | 12.4% | 4.0% |
每股收益（稀释后）HPRVTY
| Q4 25 | $-0.98 | $0.86 | ||
| Q3 25 | $-0.57 | $0.40 | ||
| Q2 25 | $-1.64 | $0.46 | ||
| Q1 25 | $0.01 | $0.35 | ||
| Q4 24 | $0.54 | $0.77 | ||
| Q3 24 | $0.77 | $0.77 | ||
| Q2 24 | $0.88 | $0.45 | ||
| Q1 24 | $0.84 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $269.0M | $919.9M |
| 总债务越低越好 | $2.0B | — |
| 股东权益账面价值 | $2.7B | $7.3B |
| 总资产 | $6.5B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.75× | — |
8季度趋势，按日历期对齐
现金及短期投资HPRVTY
| Q4 25 | $269.0M | $919.9M | ||
| Q3 25 | $218.3M | $931.4M | ||
| Q2 25 | $187.4M | $991.8M | ||
| Q1 25 | $195.6M | $1.1B | ||
| Q4 24 | $526.5M | $1.2B | ||
| Q3 24 | $510.3M | $1.2B | ||
| Q2 24 | $289.7M | $2.0B | ||
| Q1 24 | $277.0M | $1.7B |
总债务HPRVTY
| Q4 25 | $2.0B | — | ||
| Q3 25 | $2.1B | — | ||
| Q2 25 | $2.2B | — | ||
| Q1 25 | $2.2B | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $1.8B | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益HPRVTY
| Q4 25 | $2.7B | $7.3B | ||
| Q3 25 | $2.8B | $7.4B | ||
| Q2 25 | $2.9B | $7.6B | ||
| Q1 25 | $3.1B | $7.6B | ||
| Q4 24 | $2.9B | $7.7B | ||
| Q3 24 | $2.9B | $7.9B | ||
| Q2 24 | $2.9B | $7.9B | ||
| Q1 24 | $2.8B | $7.8B |
总资产HPRVTY
| Q4 25 | $6.5B | $12.2B | ||
| Q3 25 | $6.7B | $12.1B | ||
| Q2 25 | $6.9B | $12.4B | ||
| Q1 25 | $7.2B | $12.4B | ||
| Q4 24 | $5.8B | $12.4B | ||
| Q3 24 | $5.8B | $12.8B | ||
| Q2 24 | $4.5B | $13.4B | ||
| Q1 24 | $4.4B | $13.4B |
负债/权益比HPRVTY
| Q4 25 | 0.75× | — | ||
| Q3 25 | 0.73× | — | ||
| Q2 25 | 0.76× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.61× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $182.4M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $114.9M | $161.8M |
| 自由现金流率自由现金流/营收 | 11.7% | 21.0% |
| 资本支出强度资本支出/营收 | 6.9% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $179.6M | $509.4M |
8季度趋势，按日历期对齐
经营现金流HPRVTY
| Q4 25 | $182.4M | $182.0M | ||
| Q3 25 | $206.9M | $138.5M | ||
| Q2 25 | $121.6M | $134.3M | ||
| Q1 25 | $56.0M | $128.2M | ||
| Q4 24 | $158.4M | $174.2M | ||
| Q3 24 | $168.8M | $147.9M | ||
| Q2 24 | $197.4M | $158.6M | ||
| Q1 24 | $143.7M | $147.6M |
自由现金流HPRVTY
| Q4 25 | $114.9M | $161.8M | ||
| Q3 25 | $142.8M | $120.0M | ||
| Q2 25 | $24.6M | $115.5M | ||
| Q1 25 | $-102.7M | $112.2M | ||
| Q4 24 | $51.9M | $149.8M | ||
| Q3 24 | $62.8M | $125.6M | ||
| Q2 24 | $63.0M | $136.6M | ||
| Q1 24 | $25.4M | $129.7M |
自由现金流率HPRVTY
| Q4 25 | 11.7% | 21.0% | ||
| Q3 25 | 15.0% | 17.2% | ||
| Q2 25 | 2.4% | 16.0% | ||
| Q1 25 | -10.1% | 16.9% | ||
| Q4 24 | 7.7% | 20.5% | ||
| Q3 24 | 9.1% | 18.4% | ||
| Q2 24 | 9.1% | 19.7% | ||
| Q1 24 | 3.7% | 20.0% |
资本支出强度HPRVTY
| Q4 25 | 6.9% | 2.6% | ||
| Q3 25 | 6.7% | 2.6% | ||
| Q2 25 | 9.3% | 2.6% | ||
| Q1 25 | 15.7% | 2.4% | ||
| Q4 24 | 15.8% | 3.4% | ||
| Q3 24 | 15.3% | 3.3% | ||
| Q2 24 | 19.3% | 3.2% | ||
| Q1 24 | 17.3% | 2.7% |
现金转化率HPRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | 33.89× | 3.03× | ||
| Q4 24 | 2.89× | 1.84× | ||
| Q3 24 | 2.24× | 1.57× | ||
| Q2 24 | 2.23× | 2.87× | ||
| Q1 24 | 1.69× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HP
| North America Solutions | $563.6M | 57% |
| International Solutions Segment | $229.3M | 23% |
| Offshore Solutions | $188.3M | 19% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
